Cargando…

Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss

BACKROUND: Only few therapeutic options exist for patients with refractory sudden idiopathic sensorineural hearing loss (SISHL). Little is known about the efficacy of second-line therapies. Rheopheresis seems to be an effective therapeutic possibility. METHODS: Between 2012 and 2015, 106 patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostal, Milan, Drsata, Jakub, Bláha, Milan, Lánská, Miriam, Chrobok, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492286/
https://www.ncbi.nlm.nih.gov/pubmed/28662721
http://dx.doi.org/10.1186/s40463-017-0228-9
_version_ 1783247296932085760
author Kostal, Milan
Drsata, Jakub
Bláha, Milan
Lánská, Miriam
Chrobok, Viktor
author_facet Kostal, Milan
Drsata, Jakub
Bláha, Milan
Lánská, Miriam
Chrobok, Viktor
author_sort Kostal, Milan
collection PubMed
description BACKROUND: Only few therapeutic options exist for patients with refractory sudden idiopathic sensorineural hearing loss (SISHL). Little is known about the efficacy of second-line therapies. Rheopheresis seems to be an effective therapeutic possibility. METHODS: Between 2012 and 2015, 106 patients with SISHL were enrolled in the study, of whom 52 were refractory to initial treatment. As salvage therapy, these patients were offered either 3 sessions of rheopheresis (33 pts) or intratympanic steroid treatment through MicroWick application (19 pts). Pure tone audiometry was performed at diagnosis, at the 1st month and the 1st year during the follow-up. RESULTS: Patients in the rheopheretic arm had higher hearing loss than in the MicroWick arm (81% vs. 52%, p = 0.04). In spite of this, there was a significant improvement for patients in the rheopheretic arm (27% of hearing loss reduction, p < 0.001) after the 1st month and this remained unchanged during the 1st year, while no improvement was seen in the MicroWick arm (0% of hearing loss reduction, p = 0.424). We found no predictive factor for steroid-failure in first-line therapy. Older age (p = 0.003), presence of vertigo (p = 0.006) and more profound initial hearing loss (p < 0.001) were identified as negative prognostic markers. CONCLUSION: Rheopheresis can be used as a potentially effective and safe salvage therapy for patients with cortico-refractory SISHL.
format Online
Article
Text
id pubmed-5492286
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54922862017-06-30 Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss Kostal, Milan Drsata, Jakub Bláha, Milan Lánská, Miriam Chrobok, Viktor J Otolaryngol Head Neck Surg Original Research Article BACKROUND: Only few therapeutic options exist for patients with refractory sudden idiopathic sensorineural hearing loss (SISHL). Little is known about the efficacy of second-line therapies. Rheopheresis seems to be an effective therapeutic possibility. METHODS: Between 2012 and 2015, 106 patients with SISHL were enrolled in the study, of whom 52 were refractory to initial treatment. As salvage therapy, these patients were offered either 3 sessions of rheopheresis (33 pts) or intratympanic steroid treatment through MicroWick application (19 pts). Pure tone audiometry was performed at diagnosis, at the 1st month and the 1st year during the follow-up. RESULTS: Patients in the rheopheretic arm had higher hearing loss than in the MicroWick arm (81% vs. 52%, p = 0.04). In spite of this, there was a significant improvement for patients in the rheopheretic arm (27% of hearing loss reduction, p < 0.001) after the 1st month and this remained unchanged during the 1st year, while no improvement was seen in the MicroWick arm (0% of hearing loss reduction, p = 0.424). We found no predictive factor for steroid-failure in first-line therapy. Older age (p = 0.003), presence of vertigo (p = 0.006) and more profound initial hearing loss (p < 0.001) were identified as negative prognostic markers. CONCLUSION: Rheopheresis can be used as a potentially effective and safe salvage therapy for patients with cortico-refractory SISHL. BioMed Central 2017-06-29 /pmc/articles/PMC5492286/ /pubmed/28662721 http://dx.doi.org/10.1186/s40463-017-0228-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Research Article
Kostal, Milan
Drsata, Jakub
Bláha, Milan
Lánská, Miriam
Chrobok, Viktor
Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss
title Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss
title_full Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss
title_fullStr Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss
title_full_unstemmed Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss
title_short Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss
title_sort rheopheresis in treatment of idiopathic sensorineural sudden hearing loss
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492286/
https://www.ncbi.nlm.nih.gov/pubmed/28662721
http://dx.doi.org/10.1186/s40463-017-0228-9
work_keys_str_mv AT kostalmilan rheopheresisintreatmentofidiopathicsensorineuralsuddenhearingloss
AT drsatajakub rheopheresisintreatmentofidiopathicsensorineuralsuddenhearingloss
AT blahamilan rheopheresisintreatmentofidiopathicsensorineuralsuddenhearingloss
AT lanskamiriam rheopheresisintreatmentofidiopathicsensorineuralsuddenhearingloss
AT chrobokviktor rheopheresisintreatmentofidiopathicsensorineuralsuddenhearingloss